Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
about
Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trialsTargeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsSafety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of miceHead-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registrySerious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Rheumatoid arthritis and periodontitis - inflammatory and infectious connections. Review of the literature.Increased risk of revision for infection in rheumatoid arthritis patients with total hip replacementsHyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Brahma-related gene 1 induces apoptosis in a p53-dependent manner in human rheumatoid fibroblast-like synoviocyte MH7AAnti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis.Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis.Could retinoids be a potential treatment for rheumatic diseases?Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.Safety issues and concerns of new immunomodulators in rheumatology.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.Urinary free light chains may help to identify infection in patients with elevated systemic inflammation due to rheumatic disease.Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inceptionThe association between serious infection and disease outcome in patients with rheumatoid arthritis.Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.Cataract Surgery in Behçet's Disease Patients One Week after Infliximab AdministrationReactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis.Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice.RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.Risk and management of intra-abdominal abscess in Crohn's disease treated with infliximab.
P2860
Q27015772-6CBD53F8-68B6-43B1-8708-6F052B7A2BA7Q28073436-09E130A2-E19C-49D3-A819-386836226D76Q30891297-45710571-30A6-4587-B8FF-529E7EFEE4E2Q33778719-435F2434-922F-4352-8A14-036D8AAE2C2FQ34012929-990BAD67-3DFF-4D8A-AD2A-4D221F336EB9Q34363191-44E12366-098C-4CAC-8914-1202E97B634BQ35258244-AE78BA1F-8489-49CA-90B1-355D051E2CF5Q35705082-4EE1435E-0DD6-438B-86E5-49F251F6CFBFQ35758617-94BC19AF-4A5C-47CE-84E5-C92C1365E407Q35885274-BCC6DA01-AF2D-4BFE-BCD5-E90C84A4A068Q36872163-51BA7C4E-AF40-42D7-9196-8D472E65BE99Q37358271-F0B04B9A-5A55-449F-AE62-22F1081E3B34Q37463702-5DA58D77-705C-4E18-8511-CBE0D86C01E2Q37530496-B9C4E3E6-14E2-4078-811F-6CB88795E67FQ37729543-BD9806D5-CB5B-4B4D-BFD8-A933831E6666Q37987077-18F835CA-09A0-4709-BF8C-BE0641DEC520Q38067609-BFC9B79F-E419-4D46-8774-85371BAC24AEQ38171360-927359EA-77EA-4639-8F0C-A1AB92AF160FQ38176745-F17ED0F0-1145-42B3-A292-AD6C151B6764Q38183297-0EC2BADB-E9B9-4617-A677-394CF8D747CFQ38221096-6AF85BF6-E879-4282-BEBB-B65DBF58D472Q38245616-EDF9A09A-4C9E-4627-9148-3E14572237EDQ38292111-1013355C-F27B-45D0-B0CA-05D1D496A5CAQ38611360-FBAB3D87-0C9F-4E47-A38E-6888F8B0617CQ38664981-87CE12D8-A9E3-4604-BA28-4B248E3680F7Q40326976-8F811C9D-DDA7-4A7A-9CDA-A4644D7C7636Q40570832-B1E773B1-1FD0-427E-B15C-82EC5A6A48D0Q40868036-89733B76-1613-4443-A288-E095241BEF83Q41605320-1DC7AD14-2659-4FB1-88C3-C5082BBF717DQ42182730-402611C9-84BE-4236-942D-C0F30637D8EEQ42227093-6A0A4973-6992-4B52-A0D7-B323F04FA151Q42650039-19329782-69C1-4092-8BF5-9B2DC2561C78Q45098990-4F8D32CF-A646-4BAD-B497-3E1886CE9CC5Q46030948-829C58A0-CBD5-445A-B2DD-F4450D4A723DQ46299592-18A454A8-DEB7-4504-B1AB-92FB4964AD3EQ46339522-7693882D-2B1E-4E63-96BE-54ACF6CCB709Q47662522-307A3FB5-62A9-4D08-8976-52AA1F624040Q49387533-FDF78952-0793-4F7D-9C5A-760BAF4CA366Q50207113-CCCB5FC1-9D95-4253-BBB6-907B4A5B8681Q50689278-B3846B52-06A0-4534-98D7-109F9696D0AE
P2860
Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Incidence and risk factors for ...... Patients for Longterm Safety.
@en
Incidence and risk factors for ...... Patients for Longterm Safety.
@nl
type
label
Incidence and risk factors for ...... Patients for Longterm Safety.
@en
Incidence and risk factors for ...... Patients for Longterm Safety.
@nl
prefLabel
Incidence and risk factors for ...... Patients for Longterm Safety.
@en
Incidence and risk factors for ...... Patients for Longterm Safety.
@nl
P2093
P356
P1476
Incidence and risk factors for ...... Patients for Longterm Safety.
@en
P2093
Akira Hashiramoto
Atsuo Nakajima
Hideto Kameda
Hiroaki Ida
Katsumi Eguchi
Kazuyoshi Saito
Masayoshi Harigai
Michi Tanaka
Mitsuhiro Takeno
Naoto Tamura
P304
P356
10.3899/JRHEUM.101009
P407
P577
2011-04-15T00:00:00Z